nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

28.06.2016 | Original Article

Striatal hypometabolism in premanifest and manifest Huntington’s disease patients

verfasst von: Diego Alfonso López-Mora, Valle Camacho, Jesús Pérez-Pérez, Saül Martínez-Horta, Alejandro Fernández, Frederic Sampedro, Alberto Montes, Gloria Andrea Lozano-Martínez, Beatriz Gómez-Anson, Jaime Kulisevsky, Ignasi Carrió

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess metabolic changes in cerebral ¹⁸F-FDG PET/CT in premanifest and manifest Huntington’s disease (HD) subjects compared to a control group and to correlate ¹⁸F-FDG uptake patterns with different disease stages.

Materials and methods

Thirty-three gene-expanded carriers (Eight males; mean age: 43 y/o; CAG > 39) were prospectively included. Based on the Unified Huntington’s Disease Rating Scale Total Motor Score and the Total Functional Capacity, subjects were classified as premanifest (preHD = 15) and manifest (mHD = 18). Estimated time disease-onset was calculated using the Langbehn formula, which allowed classifying preHD as far-to (preHD-A) and close-to (PreHD-B) disease-onset. Eighteen properly matched participants were included as a control group (CG). All subjects underwent brain ¹⁸F-FDG PET/CT and MRI. ¹⁸F-FDG PET/CT were initially assessed by two nuclear medicine physicians identifying qualitative metabolic changes in the striatum. Quantitative analysis was performed using SPM8 with gray matter atrophy correction using the BPM toolbox.

Results

Visual analysis showed a marked striatal hypometabolism in mHD. A normal striatal distribution of ¹⁸F-FDG uptake was observed for most of the preHD subjects. Quantitative analysis showed a significant striatal hypometabolism in mHD subjects compared to CG (p < 0.001 uncorrected, k = 50 voxels). In both preHD groups we observed a significant striatal hypometabolism with respect to CG (p < 0.001 uncorrected, k = 50 voxels). In mHD subjects we observed a significant striatal hypometabolism with respect to both preHD groups (p < 0.001 uncorrected, k = 50 voxels).

Conclusion

¹⁸F-FDG PET/CT might be a helpful tool to identify patterns of glucose metabolism in the striatum across the stages of HD and might be relevant in assessing the clinical status of gene-expanded HD carriers due to the fact that dysfunctional glucose metabolism begins at early preHD stages of the disease. ¹⁸F-FDG PET/CT appears as a promising method to monitor the response to disease-modifying therapies even if applied in premanifest subjects.

Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord. 1996;11(2):136–42.

The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–83.

Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington’s disease pathology. Proc Natl Acad Sci U S A. 1999;96(8):4604–9.CrossRefPubMedPubMedCentral

Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med. 2006;47(2):215–22.PubMed

Politis M, Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol. 2012;259(9):1769–80.CrossRefPubMed

Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington’s disease. Brain. 1990;113(5):1405–23.CrossRefPubMed

Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington’s disease progression. PET and clinical observations. Brain. 1999;122(1):2353–63.CrossRefPubMed

Paulsen JS. Functional imaging in Huntington’s disease. Exp Neurol. 2009;216(2):272–7.CrossRefPubMed

Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J. Cerebral metabolism and atrophy in Huntington’s disease determined by 18FDG and computed tomographic scan. Ann Neurol. 1982;12(5):425–34.CrossRefPubMed

10.

Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington’s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986;20(3):296–303.CrossRefPubMed

11.

Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington’s disease. Neurology. 1986;36(7):888–94.CrossRefPubMed

12.

Young AB, Penney JB, Starosta-Rubinstein S, Markel D, Berent S, Rothley J, et al. Normal caudate glucose metabolism in persons at risk for Huntington’s disease. Arch Neurol. 1987;44(3):254–7.CrossRefPubMed

13.

Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WR. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington’s disease. Neurology. 1987;37(9):1441–7.CrossRefPubMed

14.

Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. N Engl J Med. 1987;316(7):357–62.CrossRefPubMed

15.

Kuwert T, Ganslandt T, Jansen P, Jülicher F, Lange H, Herzog H, et al. Influence of size of regions of interest on PET evaluation of caudate glucose consumption. J Comput Assist Tomogr. 1992;16(5):789–94.CrossRefPubMed

16.

Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain. 1996;119(6):2085–95.CrossRefPubMed

17.

Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39(6):1030–6.CrossRefPubMed

18.

Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996;11:136–42.CrossRef

19.

Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, et al. Functional decline in Huntington’s disease. Mov Disord. 1995;10:211–4.CrossRefPubMed

20.

Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RAC, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791–801.CrossRefPubMedPubMedCentral

21.

Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004;65(4):267–77.CrossRefPubMed

22.

Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8:791–801.CrossRefPubMedPubMedCentral

23.

Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36(12):2103–10.CrossRefPubMed

24.

Lange C, Suppa P, Frings L, Brenner W, Spies L, Buchert R. Optimization of statistical single subject analysis of brain FDG PET for the prognosis of mild cognitive impairment-to-Alzheimer’s disease conversion. J Alzheimers Dis. 2015;49(4):945–59.CrossRefPubMed

25.

Casanova R, Srikanth R, Baer A, Laurienti PJ, Burdette JH, Hayasaka S, et al. Biological parametric mapping: a statistical toolbox for multimodality brain image analysis. Neuroimage. 2007;34(1):137–43.CrossRefPubMed

26.

Shin H, Kim MH, Lee SJ, Lee K-H, Kim M-J, Kim JS, et al. Decreased metabolism in the cerebral cortex in early-stage Huntington’s disease: a possible biomarker of disease progression? J Clin Neurol. 2013;9(1):21–5.CrossRefPubMedPubMedCentral

27.

Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, et al. Metabolic network abnormalities in early Huntington’s disease: an [18F]FDG PET study. J Nucl Med. 2001;42(11):1591–5.PubMed

28.

Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington’s disease. Eur J Nucl Med Mol Imaging. 2016;43(6):1171–82.CrossRefPubMedPubMedCentral

29.

Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain. 2007;130(11):2858–67.CrossRefPubMedPubMedCentral

30.

Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol. 1996;53(12):1293–6.CrossRefPubMed

31.

Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington’s disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol. 1998;43(2):253–5.CrossRefPubMed

32.

Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci. 2002;5(8):731–6.PubMed

33.

Beal MF. Energetics in the pathogenesis of neurodegenrative diseases. Trends Neurosci. 2000;23:298–304.CrossRefPubMed

34.

Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging. 2009;36(7):1113–20.CrossRefPubMed

35.

Aylward EH. Changes in MRI striatal volumes as a biomarker in preclinical Huntigton’s disease. Brain Res Bull. 2007;72:152–8.CrossRefPubMed

36.

Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3–4):201–7.CrossRefPubMedPubMedCentral

37.

Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord. 2000;15(3):552–60.CrossRefPubMed

38.

Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, et al. Positron emission tomographic scan investigations of Huntington’s disease: cerebral metabolic correlates of cognitive function. Ann Neurol. 1988;23:541–6.CrossRefPubMed

Titel: Striatal hypometabolism in premanifest and manifest Huntington’s disease patients
verfasst von: Diego Alfonso López-Mora
Valle Camacho
Jesús Pérez-Pérez
Saül Martínez-Horta
Alejandro Fernández
Frederic Sampedro
Alberto Montes
Gloria Andrea Lozano-Martínez
Beatriz Gómez-Anson
Jaime Kulisevsky
Ignasi Carrió
Publikationsdatum: 28.06.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3445-y

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Guidelines to PET measurements of the target occupancy in the brain for drug development

Paraneoplastic syndrome demonstrated on 99mTc-HMDP bone scan

Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer

The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy

Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain

Reply to: Starck et al.